Britain partners with Lilly on a national obesity plan

The UK government and Eli Lilly have announced a joint program to widen access to obesity treatment across England, combining £50 million from the government with £35 million from Lilly, the maker of the weight-loss drug Mounjaro (tirzepatide) ^[1]. The initiative, called the Obesity Pathway Innovation Programme (OPIP), will fund about a dozen local projects meant to ease pressure on doctors' offices by using technology to connect patients with care ^[1].

Some of the pilot projects rely on artificial intelligence. In Norfolk, Suffolk, and northeast Essex, people worried about their weight will be able to fill out an online health check at home, which could lead to a referral for dietitian advice or specialist care without first seeing a general practitioner ^[1]. In Kent, an AI-driven WhatsApp tool will send advice on eating, activity, sleep, and stress during pregnancy and early childhood ^[1]. A separate program in Leicester and Northamptonshire will offer weight-management support through community hubs ^[1]. According to the Department of Health and Social Care, some of these projects aim to improve access to weight-loss medication "where clinically appropriate" ^[1].

Health Secretary James Murray said the projects test new ways to deliver obesity care that use current technology and sit closer to where people live, tying the effort to the government's 10-Year Health Plan and a broader push to shift the health system toward prevention ^[1]. The government says it wants to reach people in "underserved communities," including those in deprived rural and coastal areas, minority ethnic communities, people with disabilities, and families with young children ^[1].

The deal comes against a backdrop of rising obesity rates. A study cited by the outlet found that around a third of adults in England are now living with obesity, with the fastest growth among young adults, and estimated the condition costs UK society up to £107 billion a year, including more than £9 billion a year for the National Health Service ^[1]. Lilly's UK and Northern Europe president, Chris Stokes, said the company is "proud to work with the government" on projects meant to modernize obesity services ^[1]. The announcement followed Lilly's recent launch of LillyDirect in the UK, a post-prescription dispensing and delivery service that operates through a network of private, UK-regulated healthcare organizations ^[1].

Why it matters for patients

This deal is a UK government-industry partnership and does not change coverage, price, or access rules for GLP-1 drugs in the United States. But it shows how a major manufacturer of a GLP-1 medicine is experimenting with new access models — AI-based screening that skips a doctor visit, direct-to-patient delivery services, and public-private funding of obesity care — that could shape how these companies think about access programs elsewhere, including in the US, where cost and insurance coverage remain the biggest barriers for many patients seeking tirzepatide or semaglutide products ^[1].

The source material also does not detail the reported tension between Lilly and UK officials over medicine pricing referenced in some coverage of this announcement; the pharmaphorum article does not describe those negotiations, so what Lilly is seeking from the UK government on pricing, and how it connects to this obesity funding announcement, is not yet known from the available reporting ^[1].

What happens next

The pharmaphorum report does not specify start dates or an end date for the dozen OPIP pilot projects, nor does it say when results might be published or whether successful pilots would expand nationally ^[1]. Those details are not yet known based on the available source.